Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001769396 | SCV002001266 | uncertain significance | not provided | 2023-11-17 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Observed as a probable germline variant in individuals with myeloid neoplasms (PMID: 30963592); This variant is associated with the following publications: (PMID: 36672294, 30963592) |
Genetic Services Laboratory, |
RCV001821994 | SCV002071873 | uncertain significance | not specified | 2021-09-29 | criteria provided, single submitter | clinical testing | DNA sequence analysis of the DDX41 gene demonstrated a sequence change, c.38C>T, in exon 2 that results in an amino acid change, p.Thr13Ile. This sequence change does not appear to have been previously described in individuals with DDX41-related disorders and has been described in the gnomAD database with a frequency of 0.23% in the Ashkenazi Jewish subpopulation (dbSNP rs61736559). The p.Thr13Ile change affects a poorly conserved amino acid residue located in a domain of the DDX41 protein that is not known to be functional. The p.Thr13Ile substitution appears to be benign using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). Due to insufficient evidence and the lack of functional studies, the clinical significance of the p.Thr13Ile change remains unknown at this time. |
Labcorp Genetics |
RCV001769396 | SCV003490529 | likely benign | not provided | 2024-08-08 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003470888 | SCV004190933 | uncertain significance | DDX41-related hematologic malignancy predisposition syndrome | 2023-11-18 | criteria provided, single submitter | clinical testing |